Research Progress on the Regulation of Osteoporosis by Oxidative Stress Based on the Nrf2 Signaling Pathway

doi:10.19586/j.2095-2341.2025.0093

Current Biotechnology ›› 2025, Vol. 15 ›› Issue (6): 985-991.DOI: 10.19586/j.2095-2341.2025.0093

• Reviews • Previous Articles Next Articles

Research Progress on the Regulation of Osteoporosis by Oxidative Stress Based on the Nrf2 Signaling Pathway

Qingfeng YANG¹(), Siyu ZHAO², Xiaxuan CHEN¹, Xiang ZHANG¹, Yaozhong LIU¹, Yiwei JIANG³, Jiarui LIU¹()

^1.Beijing Hospital of Traditional Chinese Medicine Inner Mongolia Hospital，Inner Mongolia Bayannur 015000，China
^2.College of Traditional Chinese Medicine，Inner Mongolia Medical University，Hohhot 010110，China
^3.College of Clinical Chinese Medicine，Gansu University of Chinese Medicine，Lanzhou 730000，China

Received:2025-07-30 Accepted:2025-09-15 Online:2025-11-25 Published:2026-01-04
Contact: Jiarui LIU

Abstract

Abstract:

Osteoporosis （OP） is a metabolic bone disease characterized by reduced bone mass and deterioration of bone microarchitecture. An imbalance in bone remodeling represents the core pathological basis of OP， with oxidative stress playing a critical role in disrupting bone homeostasis and contributing to the development and progression of the disease. This article provided a systematic review of the structure and function of Nrf2， the biological effects of oxidative stress， and their interplay in the pathological mechanisms of OP. It is expected to promote future research combining single-cell omics， gene editing， and clinical translation， deepen the understanding of the regulatory mechanism of Nrf2， and promote the development of OP diagnosis and treatment technologies targeting Nrf2.

Key words: Nrf2 signaling pathway, oxidative stress, osteoporosis

摘要：

骨质疏松症（osteoporosis,OP）是一种以骨量降低、骨微结构破坏为特征的代谢性骨病，骨重塑失衡是其核心病理基础，而氧化应激在骨稳态紊乱及OP发生发展中扮演关键角色。系统综述了Nrf2的结构功能、氧化应激的生物学效应，以及二者在OP病理机制中的交互作用，以期促进未来结合单细胞组学、基因编辑及临床转化研究，深入解析Nrf2调控机制，推动靶向Nrf2的OP诊疗技术发展。

关键词: Nrf2信号通路, 氧化应激, 骨质疏松症

CLC Number:

Q291

Qingfeng YANG, Siyu ZHAO, Xiaxuan CHEN, Xiang ZHANG, Yaozhong LIU, Yiwei JIANG, Jiarui LIU. Research Progress on the Regulation of Osteoporosis by Oxidative Stress Based on the Nrf2 Signaling Pathway[J]. Current Biotechnology, 2025, 15(6): 985-991.

杨青峰, 赵思宇, 陈夏暄, 张翔, 刘耀忠, 蒋宜伟, 刘佳瑞. 基于Nrf2信号通路探讨氧化应激调控骨质疏松症的研究进展[J]. 生物技术进展, 2025, 15(6): 985-991.

Figures/Tables 3

References 38

[1]	杨青峰,张翔,刘耀忠,等.基于GPX4信号通路探讨铁死亡与骨质疏松症的作用机制及中药干预研究[J].四川中医,2025(4):203-207.
	YANG Q F, ZHANG X, LIU Y Z, et al.. Study on the mechanism of iron death and osteoporosis based on GPX4 signal pathway and the intervention of traditional Chinese medicine[J]. J. Sichuan Trad. Chin. Med., 2025(4): 203-207.
[2]	KANIS J A, COOPER C, RIZZOLI R, et al.. European guidance for the diagnosis and management of osteoporosis in postmenopausal women[J]. Osteoporos. Int., 2019, 30(1): 3-44.
[3]	中华医学会骨质疏松和骨矿盐疾病分会,章振林,夏维波,等.原发性骨质疏松症诊疗指南(2022)[J].中华内分泌代谢杂志,2023,39(5):377-406.
	Chinese Society of Osteoporosis, BONE M, ZHANG Z L, et al.. Guidelines for the diagnosis and treatment of primary osteoporosis(2022)[J]. Chin. J. Endocrinol. Metab., 2023, 39(5): 377-406.
[4]	谢恒,顾叶,顾赢楚,等.骨骼疾病中的铁死亡:骨质疏松治疗靶点[J].中国组织工程研究,2024,28(16):2613-2618.
	XIE H, GU Y, GU Y C, et al.. Ferroptosis in bone diseases: therapeutic targets of osteoporosis[J]. Chin. J. Tissue Eng. Res., 2024, 28(16): 2613-2618.
[5]	TU W, WANG H, LI S, et al.. The anti-inflammatory and anti-oxidant mechanisms of the Keap1/Nrf2/ARE signaling pathway in chronic diseases[J]. Aging Dis., 2019, 10(3): 637-651.
[6]	LIN D W, HSU Y C, CHANG C C, et al.. Insights into the molecular mechanisms of NRF2 in kidney injury and diseases[J/OL]. Int. J. Mol. Sci., 2023, 24(7): 6053[2025-08-02]. .
[7]	HAYES J D, DINKOVA-KOSTOVA A T. The Nrf2 regulatory network provides an interface between redox and intermediary metabolism[J]. Trends Biochem. Sci., 2014, 39(4): 199-218.
[8]	SEKINE H, OKAZAKI K, OTA N, et al.. The mediator subunit MED16 transduces NRF2-activating signals into antioxidant gene expression[J]. Mol. Cell. Biol., 2016, 36(3): 407-420.
[9]	WANG H, LIU K, GENG M, et al.. RXRα inhibits the NRF2-ARE signaling pathway through a direct interaction with the Neh7 domain of NRF2[J]. Cancer Res., 2013, 73(10): 3097-3108.
[10]	KHAN M Z, CHEN W, LIU X, et al.. An overview of bioactive compounds' role in modulating the Nrf2/Keap1/NF-kappaB pathway to alleviate lipopolysaccharide-induced endometritis[J]. Int. J. Mol. Sci., 2024,25(19):10319.
[11]	HU L, YIN C, ZHAO F, et al.. Mesenchymal stem cells: cell fate decision to osteoblast or adipocyte and application in osteoporosis treatment[J/OL]. Int. J. Mol. Sci., 2018, 19(2): 360[2025-08-02]. .
[12]	ZHAO X, PATIL S, XU F, et al.. Role of biomolecules in osteoclasts and their therapeutic potential for osteoporosis[J/OL]. Biomolecules, 2021, 11(5): 747[2025-08-02]. .
[13]	SONG S, GUO Y, YANG Y, et al.. Advances in pathogenesis and therapeutic strategies for osteoporosis[J/OL]. Pharmacol. Ther., 2022, 237: 108168[2025-08-02]. .
[14]	JHA S S, JEYARAMAN N, JEYARAMAN M, et al.. Cross-talks between osteoporosis and gut microbiome[J/OL]. World J. Orthop., 2025, 16(3): 102274[2025-08-02]. .
[15]	FORMAN H J, ZHANG H. Targeting oxidative stress in disease: promise and limitations of antioxidant therapy[J]. Nat. Rev. Drug Discov., 2021, 20(9): 689-709.
[16]	CASAS A I, NOGALES C, MUCKE H A M, et al.. On the clinical pharmacology of reactive oxygen species[J]. Pharmacol. Rev., 2020, 72(4): 801-828.
[17]	SUN Y X, XU A H, YANG Y, et al.. Role of Nrf2 in bone metabolism[J/OL]. J. Biomed. Sci., 2015, 22: 101[2025-08-02]. .
[18]	MOREL A, DOUAT C, BLANGY A, et al.. Bone resorption by osteoclasts involves fine tuning of RHOA activity by its microtubule-associated exchange factor GEF-H1[J/OL]. Front. Physiol., 2024, 15: 1342024[2025-08-02]. .
[19]	ATASHI F, MODARRESSI A, PEPPER M S. The role of reactive oxygen species in mesenchymal stem cell adipogenic and osteogenic differentiation: a review[J]. Stem Cells Dev., 2015, 24(10): 1150-1163.
[20]	LEE N K, CHOI Y G, BAIK J Y, et al.. A crucial role for reactive oxygen species in RANKL-induced osteoclast differentiation[J]. Blood, 2005, 106(3): 852-859.
[21]	AN Y, ZHANG H, WANG C, et al.. Activation of ROS/MAPKs/NF-κB/NLRP3 and inhibition of efferocytosis in osteoclast-mediated diabetic osteoporosis[J]. FASEB J., 2019, 33(11): 12515-12527.
[22]	AFSHARI F, BAHRI N, SAJJADI M, et al.. Menopause uncertainty: the impact of two educational interventions among women during menopausal transition and beyond[J]. Prz. Menopauzalny, 2020, 19(1): 18-24.
[23]	SOWERS M F R, EYVAZZADEH A D, MCCONNELL D, et al.. Anti-mullerian hormone and inhibin B in the definition of ovarian aging and the menopause transition[J]. J. Clin. Endocrinol. Metab., 2008, 93(9): 3478-3483.
[24]	KHOSLA S, OURSLER M J, MONROE D G. Estrogen and the skeleton[J]. Trends Endocrinol. Metab., 2012, 23(11): 576-581.
[25]	EMERTON K B, HU B, WOO A A, et al.. Osteocyte apoptosis and control of bone resorption following ovariectomy in mice[J]. Bone, 2010, 46(3): 577-583.
[26]	LEAN J M, DAVIES J T, FULLER K, et al.. A crucial role for thiol antioxidants in estrogen-deficiency bone loss[J]. J. Clin. Invest., 2003, 112(6): 915-923.
[27]	JI L L, YEO D. Oxidative stress: an evolving definition[J/OL]. Fac. Rev., 2021, 10: 13[2025-08-02]. .
[28]	LIN L, WU Q, LU F, et al.. Nrf2 signaling pathway: current status and potential therapeutic targetable role in human cancers[J/OL]. Front. Oncol., 2023, 13: 1184079[2025-08-02]. .
[29]	AHMED S M U, LUO L, NAMANI A, et al.. Nrf2 signaling pathway: pivotal roles in inflammation[J]. Biochim. Biophys. Acta Mol. Basis Dis., 2017, 1863(2): 585-597.
[30]	SUN Y X, LI L, CORRY K A, et al.. Deletion of Nrf2 reduces skeletal mechanical properties and decreases load-driven bone formation[J]. Bone, 2015, 74: 1-9.
[31]	SALIM A, NACAMULI R P, MORGAN E F, et al.. Transient changes in oxygen tension inhibit osteogenic differentiation and Runx2 expression in osteoblasts[J]. J. Biol. Chem., 2004, 279(38): 40007-40016.
[32]	CALLAWAY D A, JIANG J X. Reactive oxygen species and oxidative stress in osteoclastogenesis, skeletal aging and bone diseases[J]. J. Bone Miner. Metab., 2015, 33(4): 359-370.
[33]	PELLEGRINI G G, CREGOR M, MCANDREWS K, et al.. Nrf2 regulates mass accrual and the antioxidant endogenous response in bone differently depending on the sex and age[J/OL]. PLoS One, 2017, 12(2): e0171161[2025-08-02]. .
[34]	IBÁÑEZ L, FERRÁNDIZ M L, BRINES R, et al.. Effects of Nrf2 deficiency on bone microarchitecture in an experimental model of osteoporosis[J/OL]. Oxid. Med. Cell. Longev., 2014, 2014: 726590[2025-08-02]. .
[35]	SUN X, ZHANG B, PAN X, et al.. Octyl itaconate inhibits osteoclastogenesis by suppressing Hrd1 and activating Nrf2 signaling[J]. FASEB J., 2019, 33(11): 12929-12940.
[36]	江波,牟艳杰,孙勤国,等.滋阴补肾方调控Nrf2/HO-1通路抑制糖尿病性骨质疏松大鼠的氧化应激[J].中国老年学杂志,2025,45(12):2947-2951.
[37]	张卫华,陈东.叶黄素通过激活Nrf2信号传导通路抑制糖尿病性骨质疏松模型大鼠氧化应激及炎性反应的机制研究[J].临床误诊误治,2020(7):99-103.
	ZHANG W H, CHEN D. Mechanism of lutein inhibiting oxidative stress and inflammatory response in diabetic osteoporosis model rats by activating Nrf2 signal transduction pathway[J]. Clin. Misdiag. Misth., 2020(7): 99-103.
[38]	田岳阳.白桦脂酸通过活化Nrf2/SIRT3通路缓解氧化应激对骨髓间充质干细胞的损伤[D].天津:天津医科大学,2022.

Research Progress on the Regulation of Osteoporosis by Oxidative Stress Based on the Nrf2 Signaling Pathway

RichHTML

PDF

Knowledge

Abstract

Cite this article

share this article

Figures/Tables 3

References 38

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	Tianyuan ZHAO, Jing WANG, Yulu WANG, Chunsen YUAN, Xuechai CHEN. Research Progress on Neuroprotective Effects of Betaine [J]. Current Biotechnology, 2025, 15(2): 220-225.
[2]	Changze LI, Shuai LIU, Tongxiang DIAO, Keqin ZHANG, Dingqi SUN, Hui ZHANG. Fermented Epimedium Improves Sperm Deficiency Model in Mice: Effects and Mechanisms [J]. Current Biotechnology, 2025, 15(1): 170-175.
[3]	Jianhong YANG, Boyan LIU, Jun CHEN, Zhihui QIU, Baoqiang LI, Shucun QIN, Yandong NIU, Lei HE. Effects of Pre-treatment of Nanobubble Hydrogen Water on the Mouse Psoriasis Induction by Imiquimod [J]. Current Biotechnology, 2024, 14(4): 676-684.
[4]	Jianhong YANG, Jun CHEN, Xuefei LI, Lijun LIU, Lili CHEN, Xinsuo DUAN, Shucun QIN, Lei HE. The Potential and Prospect of Molecular Hydrogen in the Treatment of Skin Diseases [J]. Current Biotechnology, 2023, 13(6): 875-881.
[5]	Junkai ZHU, Lingzhi GE, Chao ZHANG, Can CAO, Jiahui WU, Zhen MU. Inhibitory Effect of Hydrogen Molecule on Imiquimod-induced Psoriasis-like Dermatitis in Mice [J]. Current Biotechnology, 2023, 13(6): 945-953.
[6]	Shiming LI, Peng ZHANG, Pengxiang ZHAO, Fei XIE, Xiaoping CHEN, Mengyu LIU. Research Progress of Oxidative Stress and Disuse Muscular Atrophy [J]. Current Biotechnology, 2023, 13(4): 524-533.
[7]	Li CAO, Shun LUO, Shihai XING, Jinshu QIU, Zhiyong LIN, Jun LIN, Xu MENG, Feng LIU. Effects of Dioscorea opposita Extract on CHO Cell Growth and Monoclonal Antibody Expression [J]. Current Biotechnology, 2023, 13(3): 449-456.
[8]	Jingyu CAO, Chengmei LIU, Chenxu QI, Kaiyan DU, Meng CHEN, Siwei HOU. Research Progress of Nrf2 in Ferroptosis After Spinal Cord Injury [J]. Current Biotechnology, 2023, 13(2): 240-246.
[9]	Jun CHEN, Shucun QIN, Lei HE. Inhibiting Effect of Hydrogen-rich Saline on Psoriasis in Imiquimod-induced Mouse Models [J]. Current Biotechnology, 2022, 12(4): 503-509.
[10]	Yichao LIU, Chao LU, Yuhua ZHAN, Xiubin KE, Wei LU, Yongliang YAN. Expressional and Functional Characterization of the Ferric Uptake Regulator Fur in Pseudomonas stutzeri A1501 [J]. Current Biotechnology, 2022, 12(3): 387-395.
[11]	WANG Zhen, YANG Luo, LIAO Min, HAO Yarong^*. Research Progress of mTOR Pathway in Pathogenesis of Diabetic Nephropathy [J]. Curr. Biotech., 2021, 11(3): 316-321.
[12]	ZHAO Jie1, ZHANG Weijie2, CHEN Yao3, XIANG Qingfang1, ZHAO Ting1, MAO Guanghua3, FENG Weiwei3, YANG Liuqing1*. Effect of Bee Pupa Polypeptide on the Immune Activity of Macrophage RAW264.7 [J]. Curr. Biotech., 2020, 10(5): 550-556.
[13]	XIONG Yongmin, YANG Xiaoli, ZHANG Rongqiang, LI Baorong, CHEN Jinghong, DAI Xiaoxia, CHEN Qun, TAN Wuhong, ZHANG Feng. The Effect of Selenium on Endemic Diseases and its Molecular Mechanism [J]. Curr. Biotech., 2017, 7(5): 501-505.
[14]	YANG Yujie, LI Nan*. Selenoproteins and Neurodegenerative Diseases [J]. Curr. Biotech., 2017, 7(5): 511-517.
[15]	LI Jia-la, ZHANG Ya-ting, XIE Fei*. Progress on Application of Hydrogen in Cancer Prevention and Treatment [J]. Curr. Biotech., 2016, 6(3): 174-178.